Sangamo SVP sells 345,942 shares in April trade
Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock.
Rhea-AI Filing Summary
Sangamo Therapeutics SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported an open-market sale of Common Stock. She sold 345,942 shares on April 21, 2026 at a weighted-average price of $0.2578 per share in multiple trades ranging from $0.2533 to $0.2634.
Following this transaction, she directly holds 332,769 shares of Sangamo Therapeutics Common Stock. The filing does not report any derivative security exercises, indicating this was a straightforward share sale rather than an option-related transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 345,942 shares
Net Sell
1 txn
Insider
Dubois-Stringfellow Nathalie
Role
SVP-CHIEF DEVELOPMENT OFFICER
Sold
345,942 shs ($89K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 345,942 | $0.2578 | $89K |
Holdings After Transaction:
Common Stock — 332,769 shares (Direct)
Footnotes (1)
- F1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2634, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold: 345,942 shares
Weighted-average sale price: $0.2578 per share
Price range: $0.2533–$0.2634 per share
+2 more
5 metrics
Shares sold
345,942 shares
Open-market sale on April 21, 2026
Weighted-average sale price
$0.2578 per share
Common Stock sale
Price range
$0.2533–$0.2634 per share
Individual trade prices within the sale
Shares held after transaction
332,769 shares
Direct ownership post-sale
Net shares sold
345,942 shares
Net-sell direction in transaction summary
Key Terms
open-market sale, Common Stock, weighted-average price, Securities and Exchange Commission, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
weighted-average price financial
"The price reported is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Securities and Exchange Commission regulatory
"provide upon request to the staff of the Securities and Exchange Commission"
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did SGMO report for Nathalie Dubois-Stringfellow?
Sangamo Therapeutics (SGMO) reported that SVP-Chief Development Officer Nathalie Dubois-Stringfellow sold 345,942 shares of Common Stock. The sale occurred on April 21, 2026, as an open-market transaction disclosed in a Form 4 filing with regulators.
Was the SGMO insider sale by Nathalie Dubois-Stringfellow an open-market transaction?
Yes. The Form 4 identifies the transaction code as “S” and describes it as an open-market sale. The weighted-average sale price was $0.2578, based on multiple trades between $0.2533 and $0.2634 per share on April 21, 2026.
Does Nathalie Dubois-Stringfellow’s SGMO filing involve any derivatives or options?
No derivative transactions are reported in this Form 4 for Sangamo Therapeutics (SGMO). The filing lists only a non-derivative Common Stock sale and shows an empty derivative summary, indicating no option exercises or other derivative activity in this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
